Eligo Bioscience

Eligo Bioscience was founded in 2014 as a spin-off from MIT and the Rockefeller University based on the discoveries from the Lu and Marraffini labs. The company develops a new generation of biotherapeutics that enable the expression of genetic circuits within target microbial populations and treat a wide-range of bacteria-associated unmet medical needs both in humans and animals. The company has won several international awards, has raised a US$3M seed-round in July 2015 and is currently located at Institut Pasteur in the heart of Paris.

Visite el sitio web de Eligo Bioscience

Quiénes somos

Participe en el Foro

Enlaces directos

Ediciones en otros idiomas

Política de privacidad y normas de uso

Sitemap

© 2025 Foro Económico Mundial